NAMSW · NewAmsterdam Pharma Co N.V.
Price & Indicators
Up next
Latest filings
NewAmsterdam Pharma Company N.V. announced dosing the first participant in SPINOZA, a Phase 2b trial evaluating obicetrapib in approximately 400 participants with preclinical Alzheimer’s disease.
Read the 8-KQuarterly results
* Q4 derived as the full year minus Q1 to Q3.
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NAMSW
this stock
NewAmsterdam Pharma Co N.V.
|
$2.45B | -64.1% | -50.6% | — | — |
|
VRTX
Vertex Pharmaceuticals Inc
|
$134.22B | +14.9% | +46.2% | 30.8 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.02B | +5.7% | +20.8% | 20.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +605.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 105.2%
- Reported
- 25 of 200
- Top holder
- Frazier Life Sciences Man…
- Filed
- Sep 29, 2026
- This year
- 22
NewAmsterdam Pharma Company N.V. announced dosing the first participant in SPINOZA, a Phase 2b trial evaluating obicetrapib in approximately 400 participants with preclinical Alzheimer’s disease.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NAMSW | -24.7% | -51.4% | -71.5% | -34.8% | -64.1% |
| SPY | -0.1% | 0.0% | +5.8% | +0.4% | +12.2% |
| vs SPY | -24.5% | -51.4% | -77.2% | -35.1% | -76.4% |